Tu HY, YL W., et al. - In patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer, treatment-related adverse events (TRAEs) with afatinib could be lowered with no change in progression-free survival after tolerability-guided dose-adjustments, as seen in the post hoc analysis of the LUX-Lung 3 and 6 (LL3/6) phase III trials, so researchers assessed results of tolerability-guided dose adjustments of afatinib in patients enrolled in the LL3/6/7 trials in Chinese centers via this current post hoc analysis. They enrolled 299 patients with advanced EGFR mutation-positive NSCLC in Chinese centers; 68 (23%) had their afatinib dose lowered to < 40 mg/day in the first 6 months. Grade ≥ 3 TRAE occurred in 55/68 patients (81%) before dose reduction, and while 13/68 (19%) had grade ≥ 3 TRAE after dose reduction. In patients with vs in those without dose reduction, the occurrence of grade ≥ 3 TRAEs was much more common. Overall, based on the findings, experts concluded the effectiveness of tolerability-guided afatinib dose adjustment as a strategy to decrease TRAEs without impacting efficacy in Chinese patients. Median PFS was 11.0 months in both groups, and median OS did not differ significantly.